Subscribe To

Price Alert Latest News Economic Calendar News

HAE / Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon – Chief Executive Officer Stewart Strong – President of our Global Hospital business James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Group Lee Jagoda – CJS Securities Andrew Cooper – Raymond James Mike Matson – Needham & Company Michael Petusky – Barrington Research Operator Good day and thank you for standing by, and welcome to the Second Quarter 2024 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Haemonetics

Corporation

HAE

2024

Earnings

Call

Transcript

Stock

Posted: Nov 3 2023, 18:21

Author Name: Seeking Alpha

HAE News

By Seeking Alpha
November 3, 2023

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director

By Zacks Investment Research
November 3, 2023

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE)

By Zacks Investment Research
October 20, 2023

Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

By Zacks Investment Research
October 11, 2023

Haemonetics (HAE) Moves to Strong Buy: Rationale Behind the Upgrade

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy

By Zacks Investment Research
October 11, 2023

Haemonetics (HAE) Announces Agreement to Acquire OpSens

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

By Proactive Investors
October 10, 2023

Opsens stock soars on takeover deal with Haemonetics

Opsens Inc shares surged 47% to $2.84 in midday trading on Tuesday after the cardiology-focused medical device company agreed to be acquired by glob

By Zacks Investment Research
October 4, 2023

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

By Zacks Investment Research
September 25, 2023

HAE vs. SYK: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two stock

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.